公开(公告)号：US20180334693A1

公开(公告)日：2018-11-22

申请号：US15982623

申请日：2018-05-17

申请人： AJINOMOTO CO., INC.

发明人： Christine Roche ,  Benjamin Mijts ,  Peter Kelly ,  Matthew Davis ,  Sayaka Asari ,  Keita Fukui ,  Miku Toyazaki

IPC分类号： C12P7/42 ,  C12P13/12 ,  C12R1/15 ,  C12R1/19 ,  C12N15/77 ,  C12N9/10 ,  C12N9/78 ,  C12N9/88

CPC分类号： C12P7/42 ,  C12N9/1003 ,  C12N9/78 ,  C12N9/88 ,  C12N15/77 ,  C12P7/22 ,  C12P7/24 ,  C12P13/12 ,  C12R1/15 ,  C12R1/19 ,  C12Y201/02003 ,  C12Y305/0401 ,  C12Y403/01017

摘要： A method for producing an objective substance such as vanillin and vanillic acid is provided. An objective substance is produced from a carbon source or a precursor of the objective substance by using a microorganism having an objective substance-producing ability, which microorganism has been modified so as to have a specific feature, such as a reduced activity of AICAR formyltransferase/IMP cyclohydrolase, an increased activity of 3-PGDH, and/or a reduced activity of L-serine deaminase.

公开(公告)号：US20180000906A1

公开(公告)日：2018-01-04

申请号：US15543127

申请日：2016-01-15

申请人： Vedantra Phannaceuticals, Inc.

发明人： Adrienne LI ,  Jackson EBY ,  Peter C. DEMUTH

IPC分类号： A61K38/45 ,  C12N9/78 ,  C12N9/12 ,  C12N9/10 ,  A61K31/4545 ,  A61K38/50 ,  C07K14/495 ,  C07K14/47 ,  A61K39/395 ,  A61K39/39 ,  A61K39/00 ,  A61K47/69 ,  A61K31/506

CPC分类号： A61K38/45 ,  A61K9/127 ,  A61K31/4545 ,  A61K31/506 ,  A61K38/50 ,  A61K39/0011 ,  A61K39/39 ,  A61K39/395 ,  A61K39/3955 ,  A61K47/6911 ,  A61K2039/57 ,  C07K14/47 ,  C07K14/495 ,  C07K2319/10 ,  C07K2319/40 ,  C12N9/1014 ,  C12N9/12 ,  C12N9/78 ,  C12Y201/02003 ,  C12Y207/10001 ,  C12Y305/0401

摘要： The invention provides compositions including stabilized multilamellar lipid vesicles having crosslinked lipid bilayers (referred to herein as interbilayer-crosslinked multilamellar vesicles or ICMV) and including an ALK variant, pharmaceutical compositions containing vesicles (e.g., ICMV) including an ALK variant, and methods of treatment using such compositions. The invention provides compositions including stabilized multilamellar lipid vesicles with crosslinked lipid bilayers (e.g., an interbilayer-crosslinked multilamellar vesicle or ICMV) containing an Anaplastic lymphoma kinase (ALK) variant as an antigen that is associated with solid tumor cancers.

公开(公告)号：US20070015720A1

公开(公告)日：2007-01-18

申请号：US11347811

申请日：2006-02-03

申请人： Karen Bulock ,  Mark Tepper ,  John Zhang ,  Roustem Nabioullin

发明人： Karen Bulock ,  Mark Tepper ,  John Zhang ,  Roustem Nabioullin

IPC分类号： A61K31/7056

CPC分类号： C12N15/1137 ,  A61K31/7056 ,  C12N2310/14 ,  C12Y201/02003

摘要： The invention relates to methods for treating type 2 diabetes, obesity, metabolic syndrome and conditions associated with these by administering an AICAR-monophosphate (AICAR-MP) enhancing agent that increases endogenous AICAR-MP levels in a cell. Inhibition of AICAR-formyltransferase activity (AICARFT) in a cell that regulates metabolic activity (such as fat, liver, muscle, pancreatic beta or certain brain cells) increases AICAR-monophosphate levels which in turn results in activation of the AMP-kinase (AMPK) pathway, and all of the downstream functions mediated by AMPK including increased fatty acid oxidation, enhanced glucose transport and decreased fatty acid synthesis.

摘要翻译： 本发明涉及通过施用增加细胞内源性AICAR-MP水平的AICAR-一磷酸（AICAR-MP）增强剂治疗2型糖尿病，肥胖症，代谢综合征和与此相关的病症的方法。 在调节代谢活性的细胞（如脂肪，肝脏，肌肉，胰腺β或某些脑细胞）中抑制AICAR-甲酰转移酶活性（AICARFT）增加AICAR-单磷酸盐水平，这反过来导致AMP-激酶（AMPK ）途径，并且由AMPK介导的所有下游功能包括增加的脂肪酸氧化，增强的葡萄糖转运和降低的脂肪酸合成。